Literature DB >> 31966748

Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer.

Zhenxia Wang1, Jianguo Zhao1, Haiping Zhao1, Sileng A1, Zhonghua Liu1, Yanfei Zhang1, Xitao Liu1, Fei Wang1.   

Abstract

Tumor infiltrating lymphocytes in a certain tumor microenvironment are associated with the prognosis of cancer patients. The function of CD4+ and CD8+ T cells in the microenvironment of pancreatic cancer remains largely unknown. This study aimed to investigate the prognostic value of both CD4+ and CD8+ TIL subsets and their combined role in pancreatic cancer. In this study, pancreatic cancer tissues and corresponding adjacent normal tissues were collected from 90 patients. The expression levels of CD4 and CD8+ T cells in pancreatic cancer tissues were detected by immunohistochemistry method. The results showed that CD4+ iTIL expression was significantly correlated with tumor stage. CD8+ iTILs were significantly correlated with lymphatic vessel invasion and tumor stage; CD8+ sTILs not only showed correlation with lymphatic vessel invasion and tumor stage, but also had correlation with pathologic differentiation; the survival time of high CD4 expression group was longer compared to the low CD4 expression group. CD4+ T cells were capable of killing tumor cells and prolonging the survival time of patients either directly or indirectly. According to Cox regression analysis, it was indicated that pathological differentiation, lymphatic vessel invasion, tumor stage, CD4+ and CD8+ TILs were the principle risk factors of pancreatic cancer prognosis. Especially multivariate analysis showed that pathological differentiation and the combination of CD4+ and CD8+ TILs expression were independent predictors of pancreatic cancer survival. Expression levels of CD4+ and CD8+ TILs in pancreatic cancer may provide promising and useful markers for prognosis of pancreatic cancer. IJCEP
Copyright © 2017.

Entities:  

Keywords:  Pancreatic cancer; marker; tumor infiltrating lymphocytes

Year:  2017        PMID: 31966748      PMCID: PMC6965435     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  8 in total

1.  Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.

Authors:  Masahiro Tsujimae; Atsuhiro Masuda; Takuya Ikegawa; Takeshi Tanaka; Jun Inoue; Hirochika Toyama; Keitaro Sofue; Hisahiro Uemura; Shinya Kohashi; Noriko Inomata; Kae Nagao; Shigeto Masuda; Shohei Abe; Masanori Gonda; Kohei Yamakawa; Shigeto Ashina; Yasutaka Yamada; Shunta Tanaka; Ryota Nakano; Arata Sakai; Takashi Kobayashi; Hideyuki Shiomi; Maki Kanzawa; Tomoo Itoh; Takumi Fukumoto; Yoshihide Ueda; Yuzo Kodama
Journal:  Ann Surg Oncol       Date:  2022-05-23       Impact factor: 5.344

2.  Impact of the tumor immune microenvironment on the outcome of pancreatic cancer: a retrospective study based on clinical pathological analysis.

Authors:  Hui Huang; Jichun Sun; Zhiqiang Li; Xianlin Zhang; Zheng Li; Hongwei Zhu; Xiao Yu
Journal:  Gland Surg       Date:  2022-02

3.  Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer.

Authors:  Cheng Ding; ZhangPing Yu; JiQiao Zhu; XianLiang Li; MengHua Dai
Journal:  Dis Markers       Date:  2022-06-14       Impact factor: 3.464

4.  Identification of Spindle and Kinetochore-Associated Family Genes as Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment.

Authors:  Yi Liu; Zong-Rui Jin; Xing Huang; Ye-Cheng Che; Qin Liu
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

5.  Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer.

Authors:  Ke Zhang; Pan-Ling Xu; Yu-Jie Li; Shu Dong; Hui-Feng Gao; Lian-Yu Chen; Hao Chen; Zhen Chen
Journal:  BMC Genom Data       Date:  2022-01-10

Review 6.  The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.

Authors:  Marie Muller; Vincent Haghnejad; Marion Schaefer; Guillaume Gauchotte; Bénédicte Caron; Laurent Peyrin-Biroulet; Jean-Pierre Bronowicki; Cindy Neuzillet; Anthony Lopez
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

7.  System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.

Authors:  Cheng Yan; Yandie Niu; Feng Li; Wei Zhao; Liukai Ma
Journal:  J Transl Med       Date:  2022-10-05       Impact factor: 8.440

8.  KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.

Authors:  Yuexian Li; Zhou Su; Biwei Wei; Zhihai Liang
Journal:  Int J Gen Med       Date:  2021-06-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.